Genelabs Technologies

company

About

Genelabs Technologies is a biopharmaceutical company engaged in the R&D of therapeutics for the treatment of infectious diseases.

  • 51 - 100

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$8.30M
Industries
Biopharma,Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 1983
Number Of Employee
51 - 100
Operating Status
Active

As of January 6, 2009, Genelabs Technologies Inc. was acquired by SmithKline Beecham Corporation. Genelabs Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of infectious disease therapies to improve human health. The company's product pipeline consists of infectious disease projects focusing on Hepatitis C virus infection; and late-stage clinical assets, including an investigational vaccine for hepatitis E virus that is being developed by GlaxoSmithKline; and Prestara, an investigational drug for systemic lupus erythematosus. It has license and collaboration agreement with the Novartis Institutes for BioMedical Research for HCV polymerase non-nucleoside discovery research. Genelabs Technologies also has a collaborative research agreement with the National Health Research Institutes and Genovate Biotechnology Co., Ltd. to discover and develop compounds that target the hepatitis C virus. The company was founded in 1983 and is headquartered in Redwood City, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$8.30M
Genelabs Technologies has raised a total of $8.30M in funding over 2 rounds. Their latest funding was raised on Jun 27, 2006 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 27, 2006 Series Unknown $8.30M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Genelabs Technologies is funded by 2 investors. Centrecourt Asset Management and Fort Mason Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Centrecourt Asset Management Series Unknown
Fort Mason Capital Series Unknown